One of the clearest lessons from 2025’s longevity research is deceptively simple: aging is not one thing.
Inflammation. Mitochondrial dysfunction. Cellular senescence. Telomere attrition. Epigenetic drift. Nutrient sensing dysregulation. Stem cell exhaustion. Proteostatic collapse. Each contributes to aging. Each operates through distinct mechanisms. Each requires distinct interventions.
The fantasy of a single “aging pill” that addresses all hallmarks simultaneously is just that — a fantasy. The reality is combination protocols, carefully orchestrated, targeting multiple pathways in coordination.
This is how we will extend human healthspan. Not through silver bullets, but through strategic arsenals.
Lessons from Oncology
Cancer treatment learned this lesson decades ago. Single-agent chemotherapy rarely cures. Combination regimens — attacking cancer through multiple mechanisms simultaneously — transformed outcomes for dozens of malignancies.
The parallel to longevity is direct. Aging, like cancer, is a complex process with multiple drivers. Suppressing one pathway while leaving others untouched produces marginal benefit. Coordinated intervention across pathways produces synergy.
The longevity field is finally embracing this framework.
Current Combination Approaches
The most promising protocols emerging from clinical research combine interventions across categories:
Senescence + Inflammation: Dasatinib-quercetin senolytics paired with anti-inflammatory agents. Clearing senescent cells reduces inflammatory signaling; direct anti-inflammatories address residual inflammation from other sources.
Metabolic + Mitochondrial: SGLT2 inhibitors (which now show telomere lengthening effects) combined with NAD+ precursors and mitochondrial uncouplers. Addressing energy metabolism at multiple levels.
Epigenetic + Structural: Partial reprogramming factors paired with collagen-supporting interventions. Reversing cellular age while maintaining tissue integrity.
These are early combinations. The field is still mapping optimal protocols. But the direction is clear.
Our Approach at Unzyme Laboratories
Unzyme Laboratories has administered combination longevity protocols to enhancement volunteers since 2023. We view this as essential to our mission.
Enhancement places demands on biological systems that baseline humans don’t experience. Enhanced cognitive processing requires sustained neuronal metabolism. Enhanced physical capability requires maintained musculoskeletal integrity. Enhanced sensory systems require preserved neural infrastructure.
We cannot enhance effectively without also preserving.
Our current standard protocol cycles through intervention categories on a quarterly basis:
- Q1: Senolytic clearing (dasatinib-quercetin or fisetin protocols)
- Q2: Mitochondrial optimization (NAD+ precursors, CoQ10, controlled fasting)
- Q3: Epigenetic maintenance (experimental reprogramming factors, under strict monitoring)
- Q4: Systemic assessment and personalized intervention based on biomarkers
This is not a static protocol. We adjust based on individual response data, emerging research, and observed outcomes across our volunteer cohort.
The Personalization Imperative
Combination protocols cannot be one-size-fits-all. Genetic variation, baseline health status, environmental factors, and enhancement load all influence optimal intervention selection.
A volunteer with enhanced cardiovascular function may require different mitochondrial support than one with enhanced neural processing. A volunteer with particular genetic variants in inflammatory pathways may need adjusted senolytic timing.
We invest heavily in continuous monitoring precisely because personalization requires continuous data.
Looking Forward
The combination approach to longevity will become standard within five years. The only question is whether protocols will be developed rigorously through controlled research or haphazardly through uncoordinated self-experimentation.
Unzyme Laboratories advocates for the former. We publish our protocols. We share our outcome data. We collaborate with academic institutions and regulatory bodies.
The goal is not proprietary advantage. The goal is human extension.
If our research helps establish safe, effective, evidence-based combination protocols for longevity — protocols that benefit humanity broadly, not just our volunteers — we will consider that success.
Enhancement without longevity is incomplete. We pursue both.
Erik Lindqvist is Chief Executive Officer of Unzyme Laboratories.
For information about participating in Unzyme Laboratories’ longevity research programs, visit our Clinical Trials page.